ADAG

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

1.88

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focusing on the innovative development of monoclonal antibody therapies for oncology. Leveraging its proprietary technologies, Adagene is pioneering next-generation antibody drug candidates aimed at improving efficacy and reducing side effects in cancer treatment. With a robust pipeline of drug candidates, the company is well-positioned to make significant advancements in the biopharmaceutical landscape, targeting unmet medical needs in cancer care.

LPTX
+368.57%
$2.05
DRCT
+3.38%
$0.11
PAVS
-92.57%
$0.07
BYND
+36.48%
$1.34
VHAI
0.00%
$0.00
NVDA
+1.64%
$179.92
KALA
+37.66%
$1.33
QTTB
+74.42%
$3.82
BITF
-5.74%
$3.28
ASST
-6.25%
$1.05
FTEL
+41.17%
$1.20
IPG
-1.95%
$24.57
PLUG
-4.47%
$1.92
AAL
-0.64%
$13.96
INTC
-1.35%
$40.01
AXDX
-61.36%
$0.03
BMNR
-12.62%
$28.94
IVP
+3.78%
$0.12
NIO
-5.81%
$5.18
TSLA
0.00%
$430.14
CHR
+4.81%
$0.04
BURU
-8.63%
$0.22
TLRY
-3.76%
$0.78
PFE
-1.82%
$25.27
F
-0.90%
$13.16
ADAP
-15.14%
$0.05
ONDS
-4.05%
$7.58
NFE
+7.37%
$1.31
CLSK
-6.75%
$14.08
BMNU
-24.98%
$6.14
MARA
-2.45%
$11.52
SOFI
-2.32%
$29.03
BTBT
-5.46%
$2.25
AAPL
+1.52%
$283.10
SNAP
-0.52%
$7.64
AHMA
+198.12%
$14.34
INHD
-22.06%
$0.17
RIVN
+1.77%
$17.16
MSTR
-3.25%
$171.42
AMZN
+0.28%
$233.88
SOND
-23.45%
$0.12
GOOGL
-1.65%
$314.89
YGMZ
-1.79%
$0.10
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BTG
-0.43%
$4.60
ACHR
-4.23%
$7.46
WBD
-0.54%
$23.87
CIFR
-3.24%
$19.69
CNEY
-9.96%
$1.31
RPGL
+5.72%
$0.42
SRM
+53.27%
$10.30
T
-0.88%
$25.79
CAN
-6.15%
$0.94
EXK
-5.33%
$9.40
RIG
-1.36%
$4.35
DNN
-1.56%
$2.52
HOOD
-4.08%
$123.24
AMD
+1.02%
$219.76
GRAB
-3.30%
$5.27
BAC
-0.76%
$53.24
WULF
-1.35%
$15.30
BBD
-2.16%
$3.62
RGTI
-8.29%
$23.45
WLGS
-5.57%
$0.04
GOOG
-1.56%
$315.12
MTSR
-0.35%
$70.50
HBAN
+1.47%
$16.54
PLTR
-0.56%
$167.49
KVUE
-0.74%
$17.22
AG
+1.90%
$15.52
PLTD
+0.71%
$7.09
CRWV
+5.38%
$77.06
HPE
+0.32%
$21.94
APLD
+4.09%
$28.21
NFLX
+1.44%
$109.13
PRPH
-7.51%
$0.19
HL
+1.66%
$17.10
ITUB
-1.41%
$7.69
MSFT
-1.07%
$486.74
AFMD
-34.94%
$0.18
VALE
+0.63%
$12.69
AVGO
-4.18%
$386.08
CPNG
-5.36%
$26.65
IREN
+1.42%
$48.49
SOUN
-4.39%
$11.52
RUBI
-13.53%
$0.13
AGNC
-0.28%
$10.46
SMCI
-1.29%
$33.41
CDE
-1.79%
$16.96
SMR
-9.60%
$18.08
BTE
0.00%
$3.22
CMG
-0.81%
$34.24
GPUS
-10.78%
$0.26
DVLT
-6.89%
$1.89
TE
+8.49%
$4.47
ALIT
+3.89%
$2.36
TSLG
+0.10%
$9.27
VZ
-0.90%
$40.74
LPTX
+368.57%
$2.05
DRCT
+3.38%
$0.11
PAVS
-92.57%
$0.07
BYND
+36.48%
$1.34
VHAI
0.00%
$0.00
NVDA
+1.64%
$179.92
KALA
+37.66%
$1.33
QTTB
+74.42%
$3.82
BITF
-5.74%
$3.28
ASST
-6.25%
$1.05
FTEL
+41.17%
$1.20
IPG
-1.95%
$24.57
PLUG
-4.47%
$1.92
AAL
-0.64%
$13.96
INTC
-1.35%
$40.01
AXDX
-61.36%
$0.03
BMNR
-12.62%
$28.94
IVP
+3.78%
$0.12
NIO
-5.81%
$5.18
TSLA
0.00%
$430.14
CHR
+4.81%
$0.04
BURU
-8.63%
$0.22
TLRY
-3.76%
$0.78
PFE
-1.82%
$25.27
F
-0.90%
$13.16
ADAP
-15.14%
$0.05
ONDS
-4.05%
$7.58
NFE
+7.37%
$1.31
CLSK
-6.75%
$14.08
BMNU
-24.98%
$6.14
MARA
-2.45%
$11.52
SOFI
-2.32%
$29.03
BTBT
-5.46%
$2.25
AAPL
+1.52%
$283.10
SNAP
-0.52%
$7.64
AHMA
+198.12%
$14.34
INHD
-22.06%
$0.17
RIVN
+1.77%
$17.16
MSTR
-3.25%
$171.42
AMZN
+0.28%
$233.88
SOND
-23.45%
$0.12
GOOGL
-1.65%
$314.89
YGMZ
-1.79%
$0.10
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BTG
-0.43%
$4.60
ACHR
-4.23%
$7.46
WBD
-0.54%
$23.87
CIFR
-3.24%
$19.69
CNEY
-9.96%
$1.31
RPGL
+5.72%
$0.42
SRM
+53.27%
$10.30
T
-0.88%
$25.79
CAN
-6.15%
$0.94
EXK
-5.33%
$9.40
RIG
-1.36%
$4.35
DNN
-1.56%
$2.52
HOOD
-4.08%
$123.24
AMD
+1.02%
$219.76
GRAB
-3.30%
$5.27
BAC
-0.76%
$53.24
WULF
-1.35%
$15.30
BBD
-2.16%
$3.62
RGTI
-8.29%
$23.45
WLGS
-5.57%
$0.04
GOOG
-1.56%
$315.12
MTSR
-0.35%
$70.50
HBAN
+1.47%
$16.54
PLTR
-0.56%
$167.49
KVUE
-0.74%
$17.22
AG
+1.90%
$15.52
PLTD
+0.71%
$7.09
CRWV
+5.38%
$77.06
HPE
+0.32%
$21.94
APLD
+4.09%
$28.21
NFLX
+1.44%
$109.13
PRPH
-7.51%
$0.19
HL
+1.66%
$17.10
ITUB
-1.41%
$7.69
MSFT
-1.07%
$486.74
AFMD
-34.94%
$0.18
VALE
+0.63%
$12.69
AVGO
-4.18%
$386.08
CPNG
-5.36%
$26.65
IREN
+1.42%
$48.49
SOUN
-4.39%
$11.52
RUBI
-13.53%
$0.13
AGNC
-0.28%
$10.46
SMCI
-1.29%
$33.41
CDE
-1.79%
$16.96
SMR
-9.60%
$18.08
BTE
0.00%
$3.22
CMG
-0.81%
$34.24
GPUS
-10.78%
$0.26
DVLT
-6.89%
$1.89
TE
+8.49%
$4.47
ALIT
+3.89%
$2.36
TSLG
+0.10%
$9.27
VZ
-0.90%
$40.74
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.